{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:12:58Z","timestamp":1791465178089,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","content-domain":{"domain":["cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.canlet.2013.05.031","type":"journal-article","created":{"date-parts":[[2013,6,7]],"date-time":"2013-06-07T16:07:14Z","timestamp":1370621234000},"page":"167-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Reversal of ER-\u03b2 silencing by chromatin modifying agents overrides acquired tamoxifen resistance"],"prefix":"10.1016","volume":"337","author":[{"given":"Chara A.","family":"Pitta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Papageorgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiana","family":"Charalambous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas I.","family":"Constantinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2013.05.031_b0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1749-6632.1995.tb12113.x","article-title":"The role of estrogen in mammary carcinogenesis","volume":"768","author":"Fishman","year":"1995","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.canlet.2013.05.031_b0010","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev.bi.63.070194.002315","article-title":"Molecular mechanisms of action of steroid\/thyroid receptor superfamily members","volume":"63","author":"Tsai","year":"1994","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.canlet.2013.05.031_b0015","first-page":"2852","article-title":"Estrogen receptor binding to nuclei from normal and neoplastic rat mammary tissues in vitro","volume":"47","author":"Klinge","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2013.05.031_b0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0014-5793(96)00782-X","article-title":"ER beta: identification and characterization of a novel human estrogen receptor","volume":"392","author":"Mosselman","year":"1996","journal-title":"FEBS Lett."},{"key":"10.1016\/j.canlet.2013.05.031_b0025","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1126\/science.277.5331.1508","article-title":"Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites","volume":"277","author":"Paech","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.canlet.2013.05.031_b0030","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1677\/JME-08-0177","article-title":"Binding of estrogen receptor alpha\/beta heterodimers to chromatin in MCF-7 cells","volume":"43","author":"Papoutsi","year":"2009","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.canlet.2013.05.031_b0035","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1210\/me.2005-0140","article-title":"Estrogen receptor (ER) beta modulates ERalpha-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters","volume":"20","author":"Matthews","year":"2006","journal-title":"Mol. Endocrinol."},{"issue":"Suppl. 1","key":"10.1016\/j.canlet.2013.05.031_b0040","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00280-005-0107-3","article-title":"Clinical significance of estrogen receptor beta in breast cancer","volume":"56","author":"Saji","year":"2005","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.canlet.2013.05.031_b0045","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.1038\/sj.onc.1205597","article-title":"DNA methylation and cancer","volume":"21","author":"Jones","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2013.05.031_b0050","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/pros.10171","article-title":"Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma","volume":"54","author":"Fixemer","year":"2003","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2013.05.031_b0055","first-page":"245","article-title":"Selective loss of estrogen receptor beta in malignant human colon","volume":"60","author":"Foley","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2013.05.031_b0060","first-page":"2537","article-title":"Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors","volume":"61","author":"Roger","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2013.05.031_b0065","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/1097-0215(20001201)88:5<733::AID-IJC8>3.0.CO;2-M","article-title":"Quantitative analysis of estrogen receptor-beta mRNA and its variants in human breast cancers","volume":"88","author":"Iwao","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2013.05.031_b0070","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.1073\/pnas.96.10.5722","article-title":"Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells","volume":"96","author":"Lau","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2013.05.031_b0075","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/pros.10242","article-title":"Expression of ERalpha and ERbeta in prostate cancer","volume":"55","author":"Linja","year":"2003","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2013.05.031_b0080","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1158\/0008-5472.CAN-06-0402","article-title":"Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes","volume":"66","author":"Sharma","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2013.05.031_b0085","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/path.1436","article-title":"Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model","volume":"201","author":"Skliris","year":"2003","journal-title":"J. Pathol."},{"key":"10.1016\/j.canlet.2013.05.031_b0090","doi-asserted-by":"crossref","first-page":"7600","DOI":"10.1038\/sj.onc.1207100","article-title":"Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation","volume":"22","author":"Zhao","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2013.05.031_b0095","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/bjc.1984.113","article-title":"Effects of the antioestrogen tamoxifen on the cell cycle kinetics of the human breast cancer cell line, MCF-7","volume":"49","author":"Lykkesfeldt","year":"1984","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2013.05.031_b0100","first-page":"1215","article-title":"Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells","volume":"2","author":"Kumar","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2013.05.031_b0105","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1158\/1078-0432.CCR-04-0389","article-title":"Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer","volume":"10","author":"Esslimani-Sahla","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2013.05.031_b0110","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1515\/hmbci-2011-0004","article-title":"Models and mechanisms of acquired antihormone resistance in breast cancer: significant clinical progress despite limitations","volume":"9","author":"Sweeney","year":"2012","journal-title":"Horm. Mol. Biol. Clin. Investig."},{"key":"10.1016\/j.canlet.2013.05.031_b0115","doi-asserted-by":"crossref","first-page":"7316","DOI":"10.1038\/sj.onc.1206937","article-title":"Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling","volume":"22","author":"Clarke","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2013.05.031_b0120","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1677\/erc.1.00776","article-title":"Mechanisms of tamoxifen resistance","volume":"11","author":"Ring","year":"2004","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2013.05.031_b0125","first-page":"6890","article-title":"Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition","volume":"60","author":"Yang","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2013.05.031_b0130","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1210\/en.2002-220620","article-title":"Elevated levels of epidermal growth factor receptor\/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells","volume":"144","author":"Knowlden","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.canlet.2013.05.031_b0135","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.canlet.2013.05.031_b0140","doi-asserted-by":"crossref","first-page":"8226","DOI":"10.1128\/MCB.19.12.8226","article-title":"Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta","volume":"19","author":"Chang","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.canlet.2013.05.031_b0145","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1210\/me.2004-0011","article-title":"Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells","volume":"19","author":"Sharma","year":"2005","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.canlet.2013.05.031_b0150","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/sj.onc.1209102","article-title":"ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors","volume":"25","author":"Duong","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2013.05.031_b0155","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jsbmb.2012.01.009","article-title":"A differentially methylated single CpG-site is correlated with estrogen receptor alpha transcription","volume":"130","author":"Furst","year":"2012","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.canlet.2013.05.031_b0160","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00432-008-0354-x","article-title":"ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor","volume":"134","author":"Fan","year":"2008","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.canlet.2013.05.031_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2007.03.016","article-title":"Pathways to tamoxifen resistance","volume":"256","author":"Riggins","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2013.05.031_b0170","doi-asserted-by":"crossref","first-page":"5670","DOI":"10.1158\/1078-0432.CCR-04-0110","article-title":"HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study","volume":"10","author":"Arpino","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2013.05.031_b0175","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1200\/JCO.2005.01.172","article-title":"Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase","volume":"23","author":"Gutierrez","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2013.05.031_b0180","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10549-006-9323-8","article-title":"Bad expression predicts outcome in patients treated with tamoxifen","volume":"102","author":"Cannings","year":"2007","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2013.05.031_b0185","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.yexmp.2006.09.001","article-title":"Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer","volume":"82","author":"Planas-Silva","year":"2007","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.canlet.2013.05.031_b0190","doi-asserted-by":"crossref","first-page":"45282","DOI":"10.1074\/jbc.M106211200","article-title":"Estrogen response elements alter coactivator recruitment through allosteric modulation of estrogen receptor beta conformation","volume":"276","author":"Loven","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2013.05.031_b0195","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1210\/en.2003-1043","article-title":"Estrogen receptor beta isoforms exhibit differences in ligand-activated transcriptional activity in an estrogen response element sequence-dependent manner","volume":"145","author":"Ramsey","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.canlet.2013.05.031_b0200","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1210\/en.142.9.4120","article-title":"ER beta inhibits proliferation and invasion of breast cancer cells","volume":"142","author":"Lazennec","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.canlet.2013.05.031_b0205","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1677\/erc.1.00800","article-title":"Loss of ERbeta expression as a common step in estrogen-dependent tumor progression","volume":"11","author":"Bardin","year":"2004","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2013.05.031_b0210","first-page":"5421","article-title":"Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients","volume":"59","author":"Speirs","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2013.05.031_b0215","doi-asserted-by":"crossref","first-page":"7490","DOI":"10.1158\/1078-0432.CCR-04-1114","article-title":"Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer","volume":"10","author":"Hopp","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2013.05.031_b0220","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0002-9440(10)64702-5","article-title":"Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer","volume":"156","author":"Jarvinen","year":"2000","journal-title":"Am. J. Pathol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383513004175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383513004175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T00:43:27Z","timestamp":1715474607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383513004175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0304383513004175"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2013.05.031","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reversal of ER-\u03b2 silencing by chromatin modifying agents overrides acquired tamoxifen resistance","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2013.05.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}